Q3 2024 13F Holders as of 30 Sep 2024
-
Type / Class
-
Equity / Common stock, $0.08 par value
-
Number of holders
-
5
-
Total 13F shares, excl. options
-
46.5K
-
Shares change
-
-26.8K
-
Total reported value, excl. options
-
$30K
-
Value change
-
-$39.4K
-
Number of buys
-
3
-
Number of sells
-
-5
-
Price
-
$0.73
Significant Holders of China SXT Pharmaceuticals, Inc. - Common stock, $0.08 par value (SXTC) as of Q3 2024
9 filings reported holding SXTC - China SXT Pharmaceuticals, Inc. - Common stock, $0.08 par value as of Q3 2024.
China SXT Pharmaceuticals, Inc. - Common stock, $0.08 par value (SXTC) has 5 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 46.5K shares
.
Largest 9 shareholders include Baader Bank Aktiengesellschaft (15.2K shares), GSA CAPITAL PARTNERS LLP (12.3K shares), BANK OF MONTREAL /CAN/ (10K shares), UBS Group AG (8.68K shares), JPMORGAN CHASE & CO (376 shares), CITADEL ADVISORS LLC (0 shares), Qube Research & Technologies Ltd (0 shares), ACADIAN ASSET MANAGEMENT LLC (0 shares), and Virtu Financial LLC (0 shares).
This table shows the top 5 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.